3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
2
Sarcoma
1
Other neoplasm
1
Head & Neck
1
Genitourinary
1
Breast
1
Conditions
Precancerous Conditions
2
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Papillomavirus Infections
1
HIV Infections
1
Interventions
Colposcopy
5
Biopsy
3
Vaginal Smears
2
Polymerase Chain Reaction
2
Imiquimod
2
human papillomavirus vaccine, TA
1
human papillomavirus vaccine, L1 type 16, 18
1
Zoledronic Acid
1
Watchful Waiting
1
Tretinoin
1
Transurethral Resection of Prostate
1
Spectrum Analysis
1
Spectrometry, Fluorescence
1
Sodium Chloride
1
Pregnancy Tests
1
Papanicolaou Test
1
Microarray Analysis
1
Immunohistochemistry
1
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
1
Human Papillomavirus DNA Tests
1
Histological Techniques
1
Folic Acid
1
Fluorophotometry
1
Flow Cytometry
1
Fenretinide
1
Eflornithine
1
Conization
1
Acetic Acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Uterine Cervical Dysplasia
×
Flow Cytometry
×
Other neoplasm
×
Clear all
NCT00629577
2017-02-01
SAGE
British Columbia Cancer Agency
Phase 1
Terminated
50 enrolled